Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Three Brain Diseases Linked by Toxic Form of Same Neural Protein

03.02.2010
For the first time, researchers from the University of Pennsylvania School of Medicine have found that three different degenerative brain disorders are linked by a toxic form of the same protein.

The protein, called Elk-1, was found in clumps of misshaped proteins that are the hallmarks of Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease.

“These results suggest a molecular link between the presence of inclusions and neuronal loss that is shared across a spectrum of neurodegenerative disease,” notes senior author, James Eberwine, PhD, co-director of the Penn Genome Frontiers Institute and the Elmer Holmes Bobst Professor of Pharmacology. “Identifying these links within the diseased microenvironment will open up novel avenues for therapeutic intervention. For example it is reasonable to now ask, “Is this molecule a possible new biomarker for these neurodegenerative diseases?” says Eberwine.

Eberwine, co-first authors Anup Sharma, an MD-PhD student, Jai-Yoon Sul, PhD, Assistant Professor of Pharmacology, both from Penn, Linda M. Callahan, PhD, from the University of Rochester Medical Center, and colleagues, report their findings this week in the online journal PLoS One.

Neurodegenerative diseases are characterized by a number of features including the protein clumps called inclusions; decline of nerve-cell synapses; and the selective loss of the nerve cells themselves.

Elk-1 resides within multiple brain areas, both in the nucleus and the cell body. Interestingly, when it is present in extensions of nerve cells called dendrites, it can initiate the death of that neuron. With this in mind the team assessed whether there is a specific dendrite form of Elk-1 or a modified form called phospho-Elk-1 (pElk-1) that might be associated with a spectrum of human neurodegenerative diseases.

First, they determined the importance of this specific modification of Elk-1 on its ability to initiate regionalized cell death. This was accomplished through site-directed mutations and insertion of the mutated Elk-1 mRNA into dendrites and cell bodies. These studies showed that a specific position on the protein could be modified in the dendrite to cause neuronal cell death.

Next, they screened tissue from a post-mortem human brain bank, specifically samples representative of the three major neurodegenerative diseases, to look for higher levels of the toxic form of Elk-1 protein and compared their findings to levels in brain tissue from age-matched control samples.

By comparing the immunoreactivity for the pElk-1 protein in diseased tissue versus control tissue, they found that pElk-1 strongly associates with the pathological markers present in cases of Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease versus disease-free tissue.

The team hopes to next expand these preliminary findings to a larger sample size of tissues from neurodegenerative disease banks, and to screen blood samples from affected individuals to assess the biomarker capacity of this form of Elk-1 and to use animal models of these illnesses to assess the biological role of this modified form of Elk-1 in the disease processes. They also will be looking for other sites of toxic changes on the Elk-1 protein and will look in other disease tissue for modified Elk-1.

The study was funded by the National Institute on Aging and the National Institute of Mental Health.

Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $3.6 billion enterprise.

Penn’s School of Medicine is currently ranked #3 in U.S. News & World Report’s survey of research-oriented medical schools, and is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $367.2 million awarded in the 2008 fiscal year.

Penn Medicine’s patient care facilities include:

The Hospital of the University of Pennsylvania – the nation’s first teaching hospital, recognized as one of the nation’s top 10 hospitals by U.S. News & World Report.

Penn Presbyterian Medical Center – named one of the top 100 hospitals for cardiovascular care by Thomson Reuters for six years.

Pennsylvania Hospital – the nation’s first hospital, founded in 1751, nationally recognized for excellence in orthopaedics, obstetrics & gynecology, and behavioral health.

Additional patient care facilities and services include Penn Medicine at Rittenhouse, a Philadelphia campus offering inpatient rehabilitation and outpatient care in many specialties; as well as a primary care provider network; a faculty practice plan; home care and hospice services; and several multispecialty outpatient facilities across the Philadelphia region.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2009, Penn Medicine provided $733.5 million to benefit our community.

Karen Kreeger | EurekAlert!
Further information:
http://www.uphs.upenn.edu

More articles from Life Sciences:

nachricht Rutgers scientists discover 'Legos of life'
23.01.2018 | Rutgers University

nachricht Researchers identify a protein that keeps metastatic breast cancer cells dormant
23.01.2018 | Institute for Research in Biomedicine (IRB Barcelona)

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Optical Nanoscope Allows Imaging of Quantum Dots

Physicists have developed a technique based on optical microscopy that can be used to create images of atoms on the nanoscale. In particular, the new method allows the imaging of quantum dots in a semiconductor chip. Together with colleagues from the University of Bochum, scientists from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute reported the findings in the journal Nature Photonics.

Microscopes allow us to see structures that are otherwise invisible to the human eye. However, conventional optical microscopes cannot be used to image...

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Rutgers scientists discover 'Legos of life'

23.01.2018 | Life Sciences

Seabed mining could destroy ecosystems

23.01.2018 | Earth Sciences

Transportable laser

23.01.2018 | Physics and Astronomy

VideoLinks Science & Research
Overview of more VideoLinks >>>